Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07801027 | A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) | not yet recruiting | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05247905 | Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial | active not recruiting | Phase 2 | 31 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05286814 | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | active not recruiting | Phase 2 / Phase 3 | 168 | Compass TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06673017 | PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 26 | PanTher TherapeuticsINDUSTRY | 2 | Sep 2, 2026 | clinicaltrials |
| NCT06728410 | A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement | recruiting | Phase 2 | 38 | Mehmet AkceOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | recruiting | N/A | 24,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07024615 | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | recruiting | Phase 1 | 25 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07463248 | PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy | recruiting | Phase 2 | 64 | Wang XinOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07786792 | Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCC(MUSE2) | not yet recruiting | — | 400 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 2, 2026 | clinicaltrials |
| NCT07795437 | GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma | recruiting | N/A | 100 | Peking University First HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07799298 | Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)(SPLENDID RCT) | not yet recruiting | N/A | 360 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05304481 | Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma | recruiting | Phase 2 | 95 | Lukas Biomedical Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05526443 | Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)(ADPACA) | recruiting | — | 1,500 | Medical University of GrazOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement(FOENIX-CCA4) | recruiting | Phase 2 | 120 | Taiho Oncology, Inc.INDUSTRY | 13 | Sep 1, 2026 | clinicaltrials |
| NCT06294548 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | recruiting | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06621472 | Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery | recruiting | N/A | 90 | Cairo UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07381660 | SBRT Versus Surgical Resection for Small HCC | recruiting | Phase 3 | 390 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07636148 | Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance(PreciseOnco) | recruiting | — | 2,000 | Mark C Burgmans, MD PhDOTHER | 2 | Sep 1, 2026 | clinicaltrials |
| NCT07796594 | Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer(SONATA) | active not recruiting | N/A | 180 | Amsterdam UMC, location VUmcOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | not yet recruiting | Phase 1 | 20 | University of Illinois at ChicagoOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05497531 | Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers | recruiting | N/A | 15 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06084013 | Use Of Indocyanine Green In Pancreas Surgery | recruiting | — | 55 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07632235 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai 6th People's HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07669727 | A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.(ADVANCE-MCD) | not yet recruiting | — | 140 | Boston Scientific CorporationINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07780357 | HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B | not yet recruiting | — | 2,000 | Beijing Friendship HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | not yet recruiting | Phase 2 | 55 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06698458 | Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer | recruiting | N/A | 50 | Alpha Tau Medical LTD.INDUSTRY | 3 | Aug 27, 2026 | clinicaltrials |
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | recruiting | Phase 1 | 200 | Sutro Biopharma, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07630961 | Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07640295 | Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations | recruiting | Phase 1 / Phase 2 | 80 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04157127 | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma(DECIST) | recruiting | Phase 1 | 18 | Diakonos Oncology CorporationINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05063565 | TheraSphere With Durvalumab and Tremelimumab for HCC(ROWAN) | active not recruiting | Phase 2 | 100 | Boston Scientific CorporationINDUSTRY | 5 | Aug 26, 2026 | clinicaltrials |
| NCT06187961 | HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma(CCGLC-011) | recruiting | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07494994 | SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent(SURGIMEDIA) | not yet recruiting | N/A | 60 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07787156 | Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial(REGENERATE) | not yet recruiting | N/A | 80 | Brigham and Women's HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04510740 | Liver Cancer Registry Platform(JADE) | active not recruiting | — | 1,000 | iOMEDICO AGINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04770896 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab(IMbrave251) | active not recruiting | Phase 3 | 557 | Hoffmann-La RocheINDUSTRY | 28 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06923475 | Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma(NEODISCO) | recruiting | Phase 2 / Phase 3 | 150 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06958328 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer(LAP100) | recruiting | Phase 3 | 356 | NRG OncologyOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07689175 | Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 3, 2026source: clinicaltrials